Events
We’re very excited to offer our course, INDE239SI: Valuation of Public Companies in the Life Sciences. This course will be taught by the SBG leadership team and invited guest lecturers offered this Fall on Tuesdays from 4:00pm - 5:00PM in LKSC 130. Students may enroll via Axess and Explore Courses. Postdocs and other Stanford affiliates are welcome to audit this course. Course description below:
Course Description
INDE 239: Valuation of Public Companies in the Life Sciences
Life Science companies are often valued with a different methodology than companies in other industries. This course will serve to teach students how to analyze a publicly traded life science company or sector using publicly available materials online such as 10-K, 13-F, conference calls, and financial & technical analysis. In addition, students will learn how to access various Stanford resources (analyst reports, Bloomberg, etc). Students will work in teams throughout class and give an investment pitch to a panel of professionals at the end of the course.
Course and registration details: INDE 239: Valuation of Public Companies in the Life Sciences
Dates/time/location: Sep 26 -Dec 5, Tuesdays, 4:00 - 5:00PM LKSC130
Questions: Clayton Brown (claybrow@stanford.edu); Roger Zhang (rszhang@stanford.edu)
Non-students register here
Course Description
INDE 239: Valuation of Public Companies in the Life Sciences
Life Science companies are often valued with a different methodology than companies in other industries. This course will serve to teach students how to analyze a publicly traded life science company or sector using publicly available materials online such as 10-K, 13-F, conference calls, and financial & technical analysis. In addition, students will learn how to access various Stanford resources (analyst reports, Bloomberg, etc). Students will work in teams throughout class and give an investment pitch to a panel of professionals at the end of the course.
Course and registration details: INDE 239: Valuation of Public Companies in the Life Sciences
Dates/time/location: Sep 26 -Dec 5, Tuesdays, 4:00 - 5:00PM LKSC130
Questions: Clayton Brown (claybrow@stanford.edu); Roger Zhang (rszhang@stanford.edu)
Non-students register here
Past events
SBG Lunch Series: Lunch with Simon Greenwood, PhD, Director of Roche Venture Fund
Deadline: May 22nd at 11:59PM
This event will take place at 6/1/2015, at 12PM.
The seats are limited to 20 people, and this lunch offers an opportunity to meet a director at one of the top pharmaceutical companies in the world. The venture fund at Roche will have different ways of thinking aboutinvestment compared to traditional institutional venture funds.
Roche Venture fund (http://www.roche.com/venturefund/venturefund_portfolio.htm) has invested in many companies, including Pharmasset (acquired by Gilead for Sovaldi), Complete Genomics, 23andMe, CytomX Therapeutics, Xenon Pharmaceuticals, and Foundation Medicine.
This event is hosted by the Stanford Biotechnology Group. Please visit our website at http://www.stanfordbiotechgroup.com and subscribe to our listserv!
Copyright © Stanford Biotech Group, All rights reserved.
This event will take place at 6/1/2015, at 12PM.
The seats are limited to 20 people, and this lunch offers an opportunity to meet a director at one of the top pharmaceutical companies in the world. The venture fund at Roche will have different ways of thinking aboutinvestment compared to traditional institutional venture funds.
Roche Venture fund (http://www.roche.com/venturefund/venturefund_portfolio.htm) has invested in many companies, including Pharmasset (acquired by Gilead for Sovaldi), Complete Genomics, 23andMe, CytomX Therapeutics, Xenon Pharmaceuticals, and Foundation Medicine.
This event is hosted by the Stanford Biotechnology Group. Please visit our website at http://www.stanfordbiotechgroup.com and subscribe to our listserv!
Copyright © Stanford Biotech Group, All rights reserved.
SBG Lunch Series: Lunch with Mike Goguen, Partner at Sequoia Capital
The seats are limited to 20 people, and this lunch offers an opportunity to meet a partner at one of the top venture capital firms in the world. One will be selected based on the quality of responses in this application. The topics discussed will center around genomics, disruptive business models, and qualities of good startups.
The deadline for this application is next Monday, February 23rd at 11:59pm.
Sequoia Capital (www.sequoiacap.com) has backed well known names such as Apple, Google, YouTube, Instagram, and WhatsApp. In addition, Sequoia has backed promising companies in the healthcare & life sciences such as Amylin, Onyx Pharmaceuticals, and SV Bio. Warren has backed Assurex Health, C12 Energy, Comprehend, FutureAdvisor, Guardant Health, Lifecode, Sunrun.
This event is hosted by the Stanford Biotechnology Business and Finance Group. Please visit our website at www.sbbfg.com and subscribe to our listserv!
The deadline for this application is next Monday, February 23rd at 11:59pm.
Sequoia Capital (www.sequoiacap.com) has backed well known names such as Apple, Google, YouTube, Instagram, and WhatsApp. In addition, Sequoia has backed promising companies in the healthcare & life sciences such as Amylin, Onyx Pharmaceuticals, and SV Bio. Warren has backed Assurex Health, C12 Energy, Comprehend, FutureAdvisor, Guardant Health, Lifecode, Sunrun.
This event is hosted by the Stanford Biotechnology Business and Finance Group. Please visit our website at www.sbbfg.com and subscribe to our listserv!
Investing in Biotech: Medicine, Innovation, and Investing with Rakesh Marwah, MD
November 7, 2014 at 1pm in LKSC 130
Palo Alto Investors, LLC (PAI) is a leading private investment firm. They make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. PAI doesn’t rent stocks, they own them. With over $1 billion in assets under management, they offer several healthcare sector funds. The seminar is open to all, and food will be provided. RSVP Here
November 7, 2014 at 1pm in LKSC 130
Palo Alto Investors, LLC (PAI) is a leading private investment firm. They make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. PAI doesn’t rent stocks, they own them. With over $1 billion in assets under management, they offer several healthcare sector funds. The seminar is open to all, and food will be provided. RSVP Here
Investing in Biotech with Adam Bristol, PhD
October 13, 2014 at 6pm in LKSC 130
Aquilo Capital is a biotech focused hedge fund in San Francisco. Join us to learn about Adam’s transition from academia to investing, and how to assess risk and rewards in biotech. The seminar is open to all, and food will be provided.
October 13, 2014 at 6pm in LKSC 130
Aquilo Capital is a biotech focused hedge fund in San Francisco. Join us to learn about Adam’s transition from academia to investing, and how to assess risk and rewards in biotech. The seminar is open to all, and food will be provided.
Economics of Biotech with Leon Chen, PhD
February 3, 2014 at 5pm in LKSC 120
The translation of basic biological and medical research to drug development is a complex transition involving the application of scientific principles to clinical and regulatory strategy in the context of varying business models. The most thoughts scientific discovery and development programs incorporate the a breadth of input from various aspect of the healthcare economic landscape.
This seminar will explore the interplay between payers and providers, biotech and pharmaceutical companies and public and private financial markets and how they influence the science of drug discovery. We will discuss who the players are, how they are incentivized and how they influence drug discovery and development.
February 3, 2014 at 5pm in LKSC 120
The translation of basic biological and medical research to drug development is a complex transition involving the application of scientific principles to clinical and regulatory strategy in the context of varying business models. The most thoughts scientific discovery and development programs incorporate the a breadth of input from various aspect of the healthcare economic landscape.
This seminar will explore the interplay between payers and providers, biotech and pharmaceutical companies and public and private financial markets and how they influence the science of drug discovery. We will discuss who the players are, how they are incentivized and how they influence drug discovery and development.
11.14.2012
Event summary
Event summary
11.02.2012
Social Hour
4:30-5:30PM
RSVP required, please contact Chris: cmstern@stanford.edu
* Food and refreshments to be provided.
Social Hour
4:30-5:30PM
RSVP required, please contact Chris: cmstern@stanford.edu
* Food and refreshments to be provided.
8.20.2012
* CAREERS IN INDUSTRY PANEL *
“Business and Management Opportunities in the Life Sciences Industry”
Monday, August 20, 2012
5:30 – 7:00pm
Li Ka Shing Center
Room 120
Career Panel:
Enjoy a discussion of topics such as career path transition from academia to industry, rewards and challenges of working in industry, and future trends in opportunities for Ph.D.’s in Life Sciences. Q&A, networking, and free dinner to follow!
Presented by:
Stanford Biosciences Student Association (SBSA)
School of Medicine Career Center (SOMCC)
Stanford Biotechnology Business and Finance Group (SBBFG)
* CAREERS IN INDUSTRY PANEL *
“Business and Management Opportunities in the Life Sciences Industry”
Monday, August 20, 2012
5:30 – 7:00pm
Li Ka Shing Center
Room 120
Career Panel:
- Jennifer Cygan, Ph.D.
- Todd Meyerrose, Ph.D.
- Kim Barnholt, Ph.D.
- Elizabeth Iorns, Ph.D.
Enjoy a discussion of topics such as career path transition from academia to industry, rewards and challenges of working in industry, and future trends in opportunities for Ph.D.’s in Life Sciences. Q&A, networking, and free dinner to follow!
Presented by:
Stanford Biosciences Student Association (SBSA)
School of Medicine Career Center (SOMCC)
Stanford Biotechnology Business and Finance Group (SBBFG)
